



Securities Code: 4523

FY 2015 (Ending March 31, 2016)
First Quarter Financial Results

Reference Data

July 31, 2015

Eisai Co., Ltd.

For Inquiries:

Public Relations: TEL +81-(0)3-3817-5120

Investor Relations: TEL +81-(0)3-3817-3016

<http://www.eisai.com/>

Forward-Looking Statements and Risk Factors

Materials and information provided in this financial disclosure may contain "forward-looking statements" based on current expectations, forecasts, estimates, business goals and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations.

Risks that may cause significant fluctuations in the consolidated results of the Eisai Group or have a material effect on investment decisions are described below. These are risk factors that have been identified and assessed as of the disclosure date of the Financial Report.

Risk factors associated with our business include, but are not limited to, challenges arising in overseas operations, uncertainties in new drug development, as well as risks related to strategic alliances with partner companies, medical cost-containment measures, generic drug products, intellectual property, possible occurrence of side effects, laws and regulations, litigation, closure or shutdown of production plants, safety and quality of raw materials, outsourcing, environmental issues, IT security and information management, financial market conditions and currency movement, internal control systems, and disasters.

This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.

1. Consolidated Statement of Income

	FY 2014				FY 2015				(billions of yen) FY 2015	
					Q1	Ratio (%)	YOY (%)	Diff.	Full year (est.)	Ratio (%)
Revenue	132.8	100.0	548.5	100.0	139.2	100.0	104.8	6.4	556.5	100.0
Cost of sales	48.1	36.2	193.6	35.3	49.4	35.5	102.7	1.3	196.0	35.2
Gross profit	84.7	63.8	354.9	64.7	89.8	64.5	106.1	5.1	360.5	64.8
Selling, general and administrative expenses	47.2	35.5	194.5	35.5	49.9	35.8	105.7	2.7	188.0	33.8
Selling expenses	16.8	12.7	70.7	12.9	16.0	11.5	94.9	(0.9)		
Personnel expenses	19.3	14.5	78.4	14.3	22.8	16.4	118.2	3.5		
Administrative and other expenses	11.0	8.3	45.4	8.3	11.1	8.0	100.6	0.1		
Research and development expenses	29.1	21.9	131.9	24.1	32.7	23.5	112.5	3.6	126.5	22.7
Other income	0.2	0.1	1.0	0.2	0.4	0.3	269.9	0.3		
Other expenses	0.1	0.1	1.1	0.2	0.0	0.0	37.9	(0.1)		
Operating profit	8.5	6.4	28.3	5.2	7.6	5.5	89.9	(0.9)	46.0	8.3
Financial income	0.6	0.4	2.4	0.4	0.7	0.5	112.9	0.1		
Financial costs	1.3	1.0	4.9	0.9	0.8	0.6	63.3	(0.5)		
Profit before income taxes	7.7	5.8	25.9	4.7	7.4	5.3	96.2	(0.3)	42.8	7.7
Income taxes	2.0	1.5	(17.6)	(3.2)	1.9	1.4	95.9	(0.1)		
Profit for the period	5.7	4.3	43.5	7.9	5.5	4.0	96.3	(0.2)	27.0	4.9
Attributable to										
Owners of the parent	5.7	4.3	43.3	7.9	5.4	3.9	95.9	(0.2)		
Non-controlling interests	0.1	0.0	0.2	0.0	0.1	0.1	146.1	0.0		
Comprehensive income for the period	0.7	0.5	114.2	20.8	20.2	14.5	2903.2	19.5		
Earnings per share (EPS, yen)									19.1	93.8
Dividends per share (DPS, yen)										150.0
Return on equity (ROE, %)										
Dividend on equity ratio (DOE, %)										
Overseas revenue ratio (%)		39.1		43.9		45.0				

* Full year estimation for selling, general and administrative expenses includes other income and other expenses.

Notes

Revenue	Growth in global brands (Halaven, Lenvima, Fycompa, BELVIQ) Growth in pharmaceutical business in China, Asia and EMEA (Europe, Middle East, Africa, Oceania)
Cost of sales ratio	Improvement due to change in the product mix
Selling, general and administrative expenses	Expenses incurred upon structural reform in the U.S
Research and development expenses	Upfront payment received in the previous corresponding period upon the execution of options related to joint development
Exchange rate effects	Revenue: 7.6 billion yen, operating profit:
Exchange rate sensitivity (annual effect of a 1 yen depreciation in currency value)	Revenue (U.S. dollars: 1.0 billion yen, Euro: 230 million yen, U.K. pounds: 40 million yen, Chinese renminbi: 2.65 billion yen) Operating profit (U.S. dollars: 560 million yen, Euro: 160 million yen, U.K. pounds: 70 million yen, Chinese renminbi: 1.0 billion yen)

2. Capital Expenditures, Depreciation and Amortization

(billions of yen)

	Q1	Full year	Q1	Difference	Full year (est.)
Capital expenditures	3.8	42.6	1.3	(2.5)	18.5
Property, plant and equipment	1.9	8.9	1.0	(0.9)	9.0
Intangible assets	1.9	33.6	0.3	(1.5)	9.5
Depreciation and amortization	9.3	38.9	10.3	1.0	35.0
Property, plant and equipment	3.4	13.9	3.5	0.1	13.5
Intangible assets	5.9	25.1	6.8	0.9	21.5

*Capital expenditures are shown on an accrual basis

3. Segment Information

1) Revenue by Reporting Segment

(billions of yen)

					CER YOY (%)
Japan Pharmaceutical Business	73.7	278.4	69.8	94.7	94.7
Americas Pharmaceutical Business	25.4	119.8	29.8	117.1	98.7
United States	25.2	119.0	29.5	116.8	98.3
China Pharmaceutical Business	9.2	41.0	12.9	141.3	118.5
Asia Pharmaceutical Business	7.1	30.9	8.6	121.3	107.5
EMEA Pharmaceutical Business	8.8	38.5	10.2	115.0	117.4
Consumer Healthcare Business Japan	3.8	17.0	4.0	106.9	106.9
Other	4.8	22.8	3.9	81.6	79.7
Consolidated Revenue	132.8	548.5	139.2	104.8	99.1

* Indicates revenue from external customers

4. Financial Results by Reporting Segment

1) Japan Pharmaceutical Business

(billions of yen)

	FY 2014		FY 2015	
	Q1	Full year	Q1	YOY (%)
Revenue	73.7	278.4	69.8	94.7
Prescription medicines	66.0	245.5	61.5	93.2
Generics	6.4	26.9	6.9	107.9
Diagnostics	1.4	6.0	1.4	104.9
Segment profit	33.9	122.4	31.3	92.3
Japan prescription medicines - revenue from major products				
Alzheimer's disease / Dementia with Lewy bodies treatment Aricept	13.4	46.9	11.4	85.1
Proton-pump inhibitor Pariet	10.8	37.1	8.4	78.0
Fully human anti-TNF- monoclonal antibody Humira	7.8	29.9	8.1	104.3
Pain treatment (neuropathic pain, fibromyalgia) Lyrica	4.3	21.5	5.7	133.4
Peripheral neuropathy treatment Methycobal	6.3	22.4	5.5	88.0
Oral anticoagulant Warfarin	2.4	8.6	2.1	85.8
Anticancer agent Halaven	1.6	6.1	1.8	116.5
Osteoporosis treatment Actonel	1.9	6.7	1.7	92.3
Insomnia treatment Lunesta	1.0	4.5	1.4	138.5
Gastritis / Gastric ulcer treatment Selbex	1.4	4.7	1.1	75.3
Anticancer agent Lenvima			0.2	

* The revenue for Pariet includes the revenue for triple formulation packs for *Helicobacter pylori* eradication, Rabecure Pack 400/800 and Rabefine Pack.

* Co-promotion income has been booked as the revenue for Lyrica.

* From the consolidated fiscal year ending March 31, 2016, the management structure for part of the costs in Japan was revised and the method for allocation of SG&A expenses changed as a result. As such, the "Japan pharmaceutical business" and "Consumer Healthcare Business—Japan" segment profit (loss) as well as "Group headquarters' management costs and other expenses" figures stated for the previous fiscal year ended March 31, 2015, have also been restated to reflect these changes.

3) China Pharmaceutical Business

(billions of yen)

FY 2014		FY 2015	
Q1	Full year	Q1	YOY (%)

5) EMEA Pharmaceutical Business (Europe, the Middle East, Africa and Oceania)

	FY 2014		FY 2015	
	Q1	Full year	Q1	YOY (%)
Revenue	8.8	38.5	10.2	115.0 <117.4>
Segment profit	1.1	6.6	1.9	172.6 <195.8>
EMEA - revenue from major products				
Anticancer agent Halaven	2.6	11.6	3.4	132.8 <134.5>
Antiepileptic agent Zonegran	1.9	8.1	2.0	104.2 <106.9>
Antiepileptic agent Zebinix	0.7	3.2	0.9	130.2 <135.0>
Antiepileptic agent Fycompa	0.5	2.4	0.7	132.4 <133.7>
Antiepileptic agent Inovelon	0.5	2.1	0.5	102.3 <103.7>
Anticancer agent Lenvima			0.0	

* Year-on-year percentage: figures shown in angle brackets "<>"

6) Consumer Healthcare Business Japan

	FY 2014		FY 2015	
	Q1	Full year	Q1	YOY (%)
Revenue	3.8	17.0	4.0	106.9
Segment profit	(0.4)	1.3	0.6	
Consumer Healthcare Business Japan - revenue from major products				
Vitamin B2 preparation, "Chocola BB Plus," etc. Chocola BB Group	2.5	10.3	2.5	101.0

(billions of yen)

5. Revenue from Major Products

1) Oncology-Related Products

	Q1	Full year	FY 2015	
			Q1	YOY (%)
Total	24.2	98.6	28.0	115.9
Halaven (Anticancer agent)	8.2	35.3	10.1	<103.0>
Japan	1.6	6.1	1.8	<115.4>
Americas	3.8	16.5	4.4	116.5
Asia	0.2	1.2	0.4	<98.6>
EMEA	2.6	11.6	3.4	198.9
Lenvima (Anticancer agent)		0.4	1.3	<174.9>
Japan			0.2	132.8
Americas		0.4	1.1	<134.5>
EMEA			0.0	
Aloxi (Antiemetic agent)	12.6	49.8	13.5	107.1
Treakisym/Symbenda (Anticancer agent)	1.0	3.7	1.1	<90.1>
Other	2.5	9.4	2.1	116.0
				<115.3>
				84.2
				<78.4>

2) Epilepsy Products

	Q1	Full year	FY 2015	
			Q1	YOY (%)
Total	7.1	31.7	8.4	119.0
Fycompa (Antiepileptic agent)	0.7	4.3	1.5	<112.0>
Americas	0.2	1.9	0.7	208.6
EMEA	0.5	2.4	0.7	<193.6>
				474.8
				<402.5>
				132.4
				<133.7>

3) Pariet/Aciphex (Proton-pump inhibitor)

(billions of yen)

	FY 2014		FY 2015	
	Q1	Full year	Q1	YOY (%)
Total	16.3	56.0	12.8	78.5 <74.5>
Japan	10.8	37.1	8.4	78.0
Americas	3.9	11.7	2.5	65.4 <55.1>
China	0.7	2.9	0.9	128.8 <108.0>
Asia	0.8	3.7	0.8	98.5 <87.3>

* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

* The revenue for Pariet in Japan includes the revenue for triple formulation packs for *Helicobacter pylori* eradication, Rabecure Pack 400/800 and Rabefine Pack.

4) Aricept (Alzheimer's disease / Dementia with Lewy bodies treatment)

(billions of yen)

	FY 2014		FY 2015	
	Q1	Full year	Q1	YOY (%)
Total	16.4	65.7	18.0	109.8 <104.5>
Japan	13.4	47.0	11.4	85.1
China	1.1	4.7	1.4	126.1 <105.7>
Asia	2.1	9.4	2.6	123.8 <110.0>

* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan.

6. Sales Forecasts by Reporting Segment (FY 2015)

(billions of yen)

	FY 2014		FY 2015	
	Q1	Full year	Q1	Full year (est.)
Japan	73.7	278.4	69.8	282.0
Prescription medicines	66.0	245.5	61.5	246.0
Alzheimer's disease / Dementia with Lewy bodies treatment				
Aricept	13.4	46.9	11.4	42.0
Fully human anti-TNF- monoclonal antibody				
Humira	7.8	29.9	8.1	34.0
Proton-pump inhibitor				
Pariet	10.8	37.1	8.4	33.0
Peripheral neuropathy treatment				
Methycobal	6.3	22.4	5.5	21.0
Anticancer agent				
Halaven	1.6	6.1	1.8	10.0
Insomnia treatment				
Lunesta	1.0	4.5	1.4	8.5
Oral anticoagulant				
Warfarin	2.4	8.6	2.1	8.0
Osteoporosis treatment				
Actonel	1.9	6.7	1.7	6.5
Gastritis / Gastric ulcer treatment				
Selbex	1.4	4.7	1.1	4.0
Generics	6.4	26.9	6.9	30.0
Diagnostics	1.4	6.0	1.4	6.0
Americas	25.4	119.8	29.8	102.0
United States	25.2	119.0	29.5	100.0
China	9.2	41.0	12.9	50.0
Asia	7.1	30.9	8.6	35.0
EMEA	8.8	38.5	10.2	45.0
Consumer Healthcare Business - Japan	3.8	17.0	4.0	17.5
Vitamin B2 preparation, "Chocola BB Plus," etc.				
Chocola BB Group	2.5	10.3	2.5	10.0
Other	4.8	22.8	3.9	25.0
Consolidated revenue	132.8	548.5	139.2	556.5
Global revenue from major products				
Aricept	16.4	65.7	18.0	61.0
Pariet/Aciphex	16.3	56.0	12.8	46.5
Halaven	8.2	35.3	10.1	47.0
Japan	1.6	6.1	1.8	10.0
Americas	3.8	16.5	4.4	19.5
Asia	0.2	1.2	0.4	1.8
EMEA	2.6	11.6	3.4	15.7
Fycompa	0.7	4.3	1.5	10.0
Americas	0.2	1.9	0.7	5.4
Asia		0.0	0.0	0.1
EMEA	0.5	2.4	0.7	4.5

7. Consolidated Statement of Comprehensive Income

(billions of yen)

	FY 2014		FY 2015		
	Q1	Full year	Q1	YOY (%)	Diff.
Profit for the period	5.7	43.5	5.5	96.3	(0.2)
Other comprehensive income					
Items that will not be reclassified to profit or loss					
Financial assets measured at fair value through other comprehensive income	0.1	3.4	2.8	4602.9	2.8
Remeasurements of defined benefit plans		5.0			
Subtotal	0.1	8.3	2.8	4602.9	2.8
Items that may be reclassified subsequently to profit or loss					
Exchange differences on translation of foreign operations	(5.3)	61.9	11.8		17.1
Cash flow hedges	0.2	0.5	0.0	18.4	(0.2)
Subtotal	(5.1)	62.4	11.8		16.9
Total other comprehensive income, net of tax	(5.0)	70.8	14.6		19.7
Comprehensive income for the period	0.7	114.2	20.2	2903.2	19.5
Attributable to					
Owners of the parent	0.6	113.9	20.1	3136.9	19.5
Non-controlling interests	0.1	0.3	0.1	142.4	0.0

8. Consolidated Statement of Cash Flows

	(billions of yen)	
FY 2014	FY 2015	
Q1	Q1	Diff.

9. Consolidated Statement of Financial Position

<Assets>

(billions of yen)

	March 31, 2015	Ratio (%)	June 30, 2015	Ratio (%)	% change	Diff.
Assets						
Non-current assets						
Property, plant and equipment	133.0	12.6	121.8	12.2	91.6	(11.2)
Goodwill	183.8	17.4	187.2	18.7	101.9	3.5
Intangible assets	127.6	12.1	123.2	12.3	96.5	(4.5)
Other financial assets	42.3	4.0	46.2	4.6	109.1	3.9
Other assets	3.4	0.3	3.2	0.3	95.8	(0.1)
Deferred tax assets	89.0	8.4	88.5	8.8	99.5	(0.4)
Total non-current assets	579.1	55.0	570.2	56.9	98.5	(8.9)
Current assets						
Inventories	87.6	8.3	89.0	8.9	101.6	1.4
Trade and other receivables	174.3	16.5	165.5	16.5	94.9	(8.8)
Other financial assets	28.4	2.7	15.0	1.5	52.8	(13.4)
Other assets	11.0	1.0	12.4	1.2	112.9	1.4
Cash and cash equivalents	173.3	16.4	138.7	13.8	80.0	(34.6)
Subtotal	474.7	45.0	420.7	42.0	88.6	(54.0)
Current assets held for sale			10.8	1.1		10.8
Total current assets	474.7	45.0	431.5	43.1	90.9	(43.2)
Total assets	1,053.8	100.0	1,001.7	100.0	95.1	(52.1)

Notes

Total assets

Decrease in cash and cash equivalents due to redemption of bonds, payment of consideration for sales rights acquired in the previous period, and payments of year-end dividends.

<Equity and Liabilities >

3) Cash Flows

(billions of yen)

	FY 2014				FY 2015
	Q1	Q2	Q3	Q4	Q1
Cash flow from operating activities	7.9	29.2	4.0	34.9	21.1
Cash flow from investing activities	(4.1)	(9.0)	(13.1)	7.3	(17.4)
Cash flow from financing activities	(28.7)	(3.3)	(1.4)	(26.3)	(42.5)
Cash and cash equivalents at the end of period	127.1	155.6	159.2	173.3	138.7
Free cash flow	4.7	24.3	(0.5)	31.9	(10.3)

* "Free cash flow" = "Net cash provided by (used in) operating activities" - "Capital expenditures (cash basis)"

4) Financial Positions

(billions of yen)

	June 30, 2014	September 30, 2014	December 31, 2014	March 31, 2015	June 30, 2015
Total assets	938.6	969.9	1,050.2	1,053.8	1,001.7
Equity	507.4	542.6	590.7	602.1	599.7
Attributable to owners of the parent	504.3	539.5	587.5	598.7	596.3
Liabilities	431.2	427.3	459.5	451.8	402.0
Bonds	30.0	30.0	30.0	30.0	
Borrowings	211.0	210.3	233.2	206.1	217.0
Ratio of equity attributable to owners of the parent (%)	53.7	55.6	55.9	56.8	59.5
Liabilities ratio (Net DER / times)	0.18	0.11	0.11	0.06	0.11

* "Liabilities ratio Net DER" = ("Interest-bearing debt" ("Bonds and borrowings") / "Cash and cash equivalents"

"Time deposits exceeding three months, etc.") / "Equity attributable to owners of the parent"

5) Changes in Quarterly Revenue from Major Products

(1) Oncology-Related Products

		FY 2014			FY 2015
	Q1	Q2	Q3	Q4	Q1
Total	24.2	22.6	25.8	26.0	28.0
Halaven (Anticancer agent)	8.2	8.3	9.3	9.5	10.1
Japan	1.6	1.4	1.6	1.5	1.8
Americas	3.8	3.8	4.3	4.5	4.4
Asia	0.2	0.3	0.3	0.4	0.4
EMEA	2.6	2.8	3.1	3.1	3.4
Lenvima (Anticancer agent)					

11. Major R&D Pipeline

In-House R&D Pipeline List

Product Name / Development Code	Additional Indication, etc.*	Development Stage**	Therapeutic Area***
New Approval			
Lenvima (Thyroid cancer)		(EU) approved	Oncology
Fycompa (Primary generalized tonic-clonic seizures)	AI	(US/EU) approved	Neurology
Submitted / Preparing for Submission			
Lenvima (Thyroid cancer)		(AS) submitted	Oncology
DC Bead (Transcatheter arterial embolization (TAE) of hypervascular tumors)	AI	(JP) submitted	Oncology

E5501 (Thrombocytopenia in chronic liver disease requiring surgery)		(JP/US/EU/AS) PIII	Other
Halaven (Non-small cell lung cancer)	AI	(JP/US/EU/AS) PIII	Oncology
Lenvima (Hepatocellular carcinoma)	AI	(JP/US/EU/CN/AS) PIII	Oncology

Halaven (Bladder cancer)	AI	(US/EU) PI/II	Oncology
E7090 (Solid tumors)		(JP) PI	Oncology
MORAb-066 (Solid tumors)		(US) PI	Oncology
E7046 (Solid tumors)		(US) PI	Oncology
BELVIQ (Obesity)		(JP) PI	Neurology
E2027 (Alzheimer's disease)		(US) PI	Neurology
MORAb-022 (Rheumatic disease)		(US) PI	Other
E6007 (Activated integrin inhibitor)		(JP) PI	Other
Halaven (Liposome formulation)	AF	(EU) PI	

(1) Oncology

Development Code: **E7389** Generic Name: **eribulin** Product Name: **Halaven**

Indications / Drug class: Anticancer agent / microtubule dynamics inhibitor

In-house

Development Code: **MORAb-004**

Indications / Drug class: Anticancer agent / humanized anti-endosialin monoclonal antibody			In-house
Description: A humanized IgG1 monoclonal antibody that targets Tumor Endothelial Marker 1 (TEM-1) / endothialin. Expected to show an antitumor effect against carcinomas that express endothialin.			
Melanoma	Study 201	US/EU: PII	Inj.
Colorectal cancer	202	US/EU: PII	Inj.
Soft tissue sarcoma	203	US/EU: PII	Inj.

Development Code: **MORAb-009** Generic Name: **amatuximab**

Indications / Drug class: Anticancer agent / chimeric anti-mesothelin monoclonal antibody			In-house
Description: A chimeric IgG1 monoclonal antibody that blocks the function of mesothelin. Expected to show an antitumor effect against carcinomas that express mesothelin.			
Mesothelioma	Study 003	US/EU: PII	Inj.

Development Code: **E7820**

Indications / Drug class: Anticancer agent / alpha 2 integrin suppressant			In-house
Description: An angiogenesis inhibitor that suppresses the expression of alpha 2 integrin, a vascular endothelial cell adhesion molecule.			
Colorectal cancer	Study 702	US/EU: PII	Oral

Development Code: **E7272** Generic Name: **denileukin diftitox** Product Name: **Ontak**

Indications / Drug class: Anticancer agent / interleukin-2 diphtheria toxin fusion protein			In-house
Description: A fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxins. Specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxins that have entered cells to inhibit protein synthesis. Already approved in the United States as a treatment for CD25 (a component of the IL-2 receptor) positive cutaneous T-cell lymphoma.			
Melanoma (Additional Indication)	Study 701	US: PII	Inj.

Development Code: **E7040** Product Name: **DC Bead**

Indications / Drug class: Embolic bead / medical device			In-license (Biocompatibles)
Description: Contains hydrophilic microspherical particles produced from cross-linked polyvinyl alcohol polymer. These embolic beads are injected through a catheter to selectively embolize targeted blood vessels. The beads are microscopic and uniformly spherical in shape, allowing for sustained embolization of targeted vessels based on vascular diameter and tumor size. Approved in Japan as a device for transcatheter arterial embolization (TAE) therapy in patients with hepatocellular carcinoma.			
Transcatheter arterial embolization (TAE) of hypervascular tumors (Additional Indication)	Study 301	JP: submitted (September 2014)	Embolic Agent

Development Code: **E7090**

Solid tumors	JP: PI	In-house	Oral
--------------	--------	----------	------

Development Code: **MORAb-066**

Solid tumors	US: PI	In-license (Janssen Biotech)	Inj.
--------------	--------	------------------------------	------

Development Code: **E7046**

Solid tumors	US PI	In-house	Oral
--------------	-------	----------	------

Development progress from April 2015 onwards

(2) Neurology

Development Code: **E2020** G0

Development Code: **E2609**

Indications / Drug class: Anti-Alzheimer's agent / beta secretase cleaving enzyme (BACE) inhibitor	In-house	
Description: BACE inhibitor. By inhibiting beta-site amyloid precursor protein cleaving enzymes (BACE), the agent reduces the amount of amyloid beta in the brain, potentially improving symptoms and slowing the progression of Alzheimer's disease.		
Alzheimer's disease	Study 202 US: PII	Oral

(3) Other (Gastrointestinal, Blood and Immunological Disorder)

Development Code: **E3810** Generic Name: **rabeprazole** Product Name: **Pariet/Aciphex**

Indications / Drug class: Proton pump inhibitor		In-house		
Description: A proton pump inhibitor approved for the treatment of gastric and duodenal ulcers, reflux esophagitis, eradication of <i>Helicobacter pylori</i> infections and triple formulation packs (combination packs) for <i>H. pylori</i> eradication which contain rabeprazole, etc. Obtained approval for prevention of recurrent gastric or duodenal ulcer caused by low-dose aspirin therapy as well as 5 mg tablet formulation in December 2014.				
Maintenance therapy for proton pump inhibitor (PPI)-resistant reflux esophagitis (Additional Indication)	Study 311	JP: PIII	Submission Target: FY2016	Oral
Functional dyspepsia (Additional Indication)	204	JP: PII		Oral

Development Code: **E5501/AKR-501** Generic Name: **avatrombopag**

et/Aciphex